leisure time -WSS

leisure time

author：focus 2025-09-02 17:49:28 - browse：213

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： The United States is paying nearly triple for new Covid vaccines

WSS

WHO recommends second malaria vaccine

European officials brace for rough respiratory virus season

AstraZeneca bets AAV gene therapy will still deliver the goods

In science, is the line between industry and academia shifting?

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Australia’s approach to dialysis celebrates life

explore

leisure time

focus

Tori Bowie and the unacceptable rates of Black maternal death

Congress extends some pandemic preparedness programs

Duchenne breakthrough therapy leaves behind pioneering families

The United States is paying nearly triple for new Covid vaccines

United colonoscopy coverage change 'may cost lives,' doctors say

AstraZeneca bets AAV gene therapy will still deliver the goods

ChatGPT in medicine: STAT answers readers' burning questions

As pharma fights Medicare drug negotiation, hospitals, docs silent

The cancer drug shortage isn’t new — and neither are the solutions

What we owe ALS patients — and why one company fell short

leisure time

What we owe ALS patients — and why one company fell short

Australia’s approach to dialysis celebrates life

Winners, losers from Medicare’s list of drugs subject to price talks

Will an HIV vaccine ever be a reality?

The United States is paying nearly triple for new Covid vaccines

How to make AI work for medicine

focus

entertainment

leisure time

hotspot